Alzinova, a Swedish biopharmaceutical company developing disease-modifying treatments against Alzheimer’s Disease, has moved into AstraZeneca’s BioVentureHub in Gothenburg.
Alzinova is specializing in the treatment of Alzheimer’s Disease by targeting the toxic amyloid-β oligomers. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that with high precision could target the toxic amyloid-β oligomers involved in the onset and progression of the disease. The vaccine is currently being prepared for the first clinical trial in patients with Alzheimer’s disease, at the turn of the year 2020/2021.
Kristina Torfgård, CEO of Alzinova, says, “We’re excited to be joining the BioVentureHub and being an active member of their collaborative innovation community. Having access to AstraZeneca’s world-class life science facilities and drug development expertise will facilitate our research and support our long-term goal to provide effective treatments to halt and reverse Alzheimer’s Disease.”
Magnus Björsne, CEO of AstraZeneca’s BioVentureHub, says, “From university research project through GU Ventures’ incubation program and onto the stock market, Alzinova has been on an exciting growth journey through the life science ecosystem. We welcome Kristina and her team to continue their progress in the BioVentureHub, and hope they will find inspiration and opportunities to collaborate, innovate and develop their research in this important area of healthcare.”
For more information, please contact:
Kristina Torfgård, CEO Alzinova
Tel. +46 (0)708-46 79 75, e-mail: firstname.lastname@example.org
Jamie Smith, AstraZeneca BioVentureHub
Tel. +46 (0)723-75 75 07, e-mail: Jamie.email@example.com
Alzinova AB is engaged in pharmaceutical research and development for treatment of Alzheimer’s disease – one of our major health scourges, without efficient treatment options. The company's patented technology enables the development of novel therapies, that with high precision could target the substances involved in the formation of the disease and render them harmless. Alzinova's focus is to develop a vaccine as a long-acting therapy for treatment and prevention of Alzheimer's disease. The vaccine is currently under preclinical development, in preparation for human clinical trials. The Company further conducts development relating to the disease. Alzinova was founded by researchers from the MIVAC research center at the University of Gothenburg, and by GU Ventures AB. Please visit www.alzinova.se
About AstraZeneca BioVentureHub
AstraZeneca started the BioVentureHub in 2014 as an open ecosystem for innovation and to strengthen the competitiveness of and dynamics in the life science industry. Based on an innovative public-private-partnership model, the BioVentureHub offers small and medium-sized companies and academic groups from Sweden and abroad a unique opportunity to co-locate with and tap into the power of AstraZeneca's world-class researchers and facilities, and to work closely with each other. There are currently 28 small and medium-sized companies, as well as 1 academic group, in the BioVentureHub. Please visit www.azbioventurehub.com